Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2017
 
PIERIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
 
 
Nevada
 
001-37471
 
EIN 30-0784346
(State of
Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
255 State Street, 9th Floor
Boston, MA 02109
United States
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 857-246-8998
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company  ý
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐






Item 7.01: Regulation FD Disclosure.

Pieris Pharmaceuticals, Inc. (“Pieris”) announced today that it has dosed the first healthy subjects in its Phase I study of PRS-060, an inhaled Anticalin® protein targeting IL-4Ra. PRS-060 is being developed in partnership with AstraZeneca AB (“AstraZeneca”), who is funding the study, while Pieris’ wholly-owned affiliate, Pieris Australia Pty Ltd., is the study sponsor.

The dosing of PRS-060 in this Phase 1 study has triggered a $12.5 million milestone payment from AstraZeneca to Pieris.
 
The information set forth under this “Item 7.01. Regulation FD Disclosure,” shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  
PIERIS PHARMACEUTICALS, INC.
 
 
Dated: December 20, 2017
  
/s/ Allan Reine
 
  
Allan Reine
 
  
Chief Financial Officer